PMS-Duloxetine 30 mg: Exceeds acceptable interim intake limit for N-nitroso-duloxetine (NDLX)
Brand(s)
Last updated
Summary
Product
PMS-Duloxetine 30 mg
Issue
Health products - Product quality
What to do
Consult your health care professional if you have any health concerns.
Affected products
Brand |
Product Name |
Market Authorization |
Dosage Form |
Strength |
Lot |
|---|---|---|---|---|---|
PMS-Duloxetine |
PMS-Duloxetine 30 mg - 100 capsules |
DIN 02429446 |
Capsule (Delayed Release) |
Duloxetine (Duloxetine Hydrochloride) 30 mg |
646038 |
Issue
Affected lot exceeds the interim acceptable intake limit for N-nitroso-duloxetine (NDLX).
What you should do
- Verify if your product is affected.
- Consult your healthcare provider prior to discontinuing use of the affected product(s), or for any health concerns.
- Contact the recalling firm if you have any questions about the recall.
- Report any health product related side effects to Health Canada.
- Report any other health product safety complaints to Health Canada.
Additional information
Background
Depth of recall: Retailers
Details
Original published date:
Alert / recall type
Health product recall
Category
Health products - Drugs
Companies
Pharmascience Inc.
6111, av. Royalmount, Suite 100
Montréal, Québec H4P 2T4
Published by
Health Canada
Audience
General public
Healthcare
Industry
Recall class
Type I
Identification number
RA-75397
Get notified
Receive notifications for new and updated recalls and alerts by category.